Drug Profile
Azemiglitazone - Metabolic Solutions Development Company
Alternative Names: MSDC-0602; MSDC-0602 potassium; MSDC-0602KLatest Information Update: 05 Sep 2023
Price :
$50
*
At a glance
- Originator Metabolic Solutions Development Company
- Developer Cirius Therapeutics; Metabolic Solutions Development Company
- Class Antihyperglycaemics; Hepatoprotectants; Insulin sensitisers; Small molecules; Thiazolidinediones; Urologics
- Mechanism of Action Mitochondrial membrane transport protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Non-alcoholic steatohepatitis
- Suspended Type 2 diabetes mellitus
- No development reported Polycystic kidney disease
Most Recent Events
- 05 Sep 2023 Chemical structure information added
- 21 Jun 2023 Pharmacodynamics data from a phase IIb trial in Non alcoholic steatohepatitis presented at the European Association for the Study of the Liver Congress 2023 (EASL-2023)
- 08 Sep 2021 Azemiglitazone is still in phase II trials for Non-alcoholic steatohepatitis in USA (Metabolic Solutions Development Company pipeline, September 2021)